Experiences of telehealth among people receiving alcohol and other drug treatment during the COVID-19 pandemic : Implications for future telehealth delivery
© 2023 The Authors. Drug and Alcohol Review published by John Wiley & Sons Australia, Ltd on behalf of Australasian Professional Society on Alcohol and other Drugs..
INTRODUCTION: The novel coronavirus (COVID-19) pandemic necessitated the rapid uptake of telehealth to deliver treatment for alcohol and other drug (AOD) concerns. However, little is known about how the move from in-person to telehealth delivery impacted clients' experience of care. This qualitative study aimed to explore experiences of telehealth among people receiving alcohol and other drug treatment during the COVID-19 pandemic, and their preferences regarding future telehealth care.
METHODS: Participants were aged 34-66 years (M = 44 years, 60% male) and were recruited from Victorian AOD treatment services and consumer networks. A total of 20 semi-structured interviews were analysed using thematic analysis.
RESULTS: Three themes were identified: (i) experiences of the practical impacts of telehealth; (ii) experiences of telehealth interactions; and (iii) preferences for future telehealth. Contextual factors, including location and socioeconomic status, were found to impact clients' ability to access reliable telehealth with sufficient privacy. While telehealth was generally associated with increased treatment engagement (for a typically stigmatised population), participants noted varying effects on the therapeutic alliance. Although in-person treatment was generally favoured, participants often valued telehealth as a modality to provide empathic care during the pandemic. Participants expressed a preference for a hybrid treatment model in the future, in which they could choose a combination of telehealth and in-person services.
CONCLUSION: Client and clinician information and training are vital to improve the future delivery of telehealth for AOD treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:43 |
|---|---|
| Enthalten in: |
Drug and alcohol review - 43(2024), 3 vom: 28. März, Seite 694-704 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Woolley, Jaimie [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Addiction |
|---|
| Anmerkungen: |
Date Completed 04.03.2024 Date Revised 04.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/dar.13797 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366461699 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366461699 | ||
| 003 | DE-627 | ||
| 005 | 20240304232159.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240108s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/dar.13797 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1316.xml |
| 035 | |a (DE-627)NLM366461699 | ||
| 035 | |a (NLM)38155522 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Woolley, Jaimie |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Experiences of telehealth among people receiving alcohol and other drug treatment during the COVID-19 pandemic |b Implications for future telehealth delivery |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.03.2024 | ||
| 500 | |a Date Revised 04.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Drug and Alcohol Review published by John Wiley & Sons Australia, Ltd on behalf of Australasian Professional Society on Alcohol and other Drugs. | ||
| 520 | |a INTRODUCTION: The novel coronavirus (COVID-19) pandemic necessitated the rapid uptake of telehealth to deliver treatment for alcohol and other drug (AOD) concerns. However, little is known about how the move from in-person to telehealth delivery impacted clients' experience of care. This qualitative study aimed to explore experiences of telehealth among people receiving alcohol and other drug treatment during the COVID-19 pandemic, and their preferences regarding future telehealth care | ||
| 520 | |a METHODS: Participants were aged 34-66 years (M = 44 years, 60% male) and were recruited from Victorian AOD treatment services and consumer networks. A total of 20 semi-structured interviews were analysed using thematic analysis | ||
| 520 | |a RESULTS: Three themes were identified: (i) experiences of the practical impacts of telehealth; (ii) experiences of telehealth interactions; and (iii) preferences for future telehealth. Contextual factors, including location and socioeconomic status, were found to impact clients' ability to access reliable telehealth with sufficient privacy. While telehealth was generally associated with increased treatment engagement (for a typically stigmatised population), participants noted varying effects on the therapeutic alliance. Although in-person treatment was generally favoured, participants often valued telehealth as a modality to provide empathic care during the pandemic. Participants expressed a preference for a hybrid treatment model in the future, in which they could choose a combination of telehealth and in-person services | ||
| 520 | |a CONCLUSION: Client and clinician information and training are vital to improve the future delivery of telehealth for AOD treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 pandemic | |
| 650 | 4 | |a addiction | |
| 650 | 4 | |a health service | |
| 650 | 4 | |a telehealth | |
| 650 | 4 | |a treatment | |
| 700 | 1 | |a Savic, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Garfield, Joshua B B |e verfasserin |4 aut | |
| 700 | 1 | |a Petukhova, Rachel |e verfasserin |4 aut | |
| 700 | 1 | |a Manning, Victoria |e verfasserin |4 aut | |
| 700 | 1 | |a Lubman, Dan I |e verfasserin |4 aut | |
| 700 | 1 | |a Barnett, Anthony |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drug and alcohol review |d 1990 |g 43(2024), 3 vom: 28. März, Seite 694-704 |w (DE-627)NLM089805186 |x 1465-3362 |7 nnns |
| 773 | 1 | 8 | |g volume:43 |g year:2024 |g number:3 |g day:28 |g month:03 |g pages:694-704 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/dar.13797 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 43 |j 2024 |e 3 |b 28 |c 03 |h 694-704 | ||